Find out more »
Find out more »
Find out more »
|Register Today for This Free Webinar: Strategic Use
of BCNU Wafers in Contemporary Care
Lynn Stuart Ashby, MD
Assistant Director, Neuro Oncology Program
Barrow Neurological Institute (BNI)
Eyas M. Hattab, MD, MBA
AJ Miller Professor and Chair
Pathology and Laboratory Medicine
Timothy C. Ryken, MD, MS, FACS, FAANS
Professor and Chief
Section of Neurosurgery
Dartmouth-Hitchcock Medical Center
In this one-hour webinar, participants will receive an overview on the practical use of BCNU Wafers for the treatment of newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation and recurrent glioblastoma multiforme as an adjunct to surgery. Neurooncology, neuropathology and neurosurgery perspectives will be presented in the discussion covering peri-operative considerations for BCNU Wafer implantation as part of a multimodal treatment plan.
IMPORTANT SAFETY INFORMATION
GLIADEL Wafer can cause fetal harm when administered to a pregnant woman. It is recommended that patients receiving GLIADEL Wafer discontinue nursing. Female patients of reproductive potential should receive counseling on pregnancy planning and prevention. Advise male patients of the potential risk of infertility and to seek counseling on fertility and family planning options prior to implantation of GLIADEL Wafer.
WARNINGS AND PRECAUTIONS
Seizures: Seizures occurred in 37% of patients treated with GLIADEL Wafers in the recurrent disease trial. New or worsening (treatment emergent) seizures occurred in 20% of patients; 54% of treatment-emergent seizures occurred within the first 5 post-operative days. The median time to onset of the first new or worsened post-operative seizure was 4 days. Institute optimal anti-seizure therapy prior to surgery. Monitor patients for seizures postoperatively.
Intracranial Hypertension: Brain edema occurred in 23% of patients treated with GLIADEL Wafers in the initial surgery trial. Additionally, one GLIADEL-treated patient experienced intracerebral mass effect unresponsive to corticosteroids which led to brain herniation. Monitor patients closely for intracranial hypertension related to brain edema, inflammation, or necrosis of the brain tissue surrounding the resection. In refractory cases, consider re-operation and removal of GLIADEL Wafers or Wafer remnants.
Impaired Neurosurgical Wound Healing: Impaired neurosurgical wound healing including wound dehiscence, delayed wound healing, and subdural, subgleal, or wound effusions occur with GLIADEL Wafer treatment. In the initial disease trial, 16% of GLIADEL Wafer-treated patients experienced impaired intracranial wound healing and 5% had cerebrospinal fluid leaks. In the recurrent disease trial, 14% of GLIADEL Wafer-treated patients experienced wound healing abnormalities. Monitor patients post-operatively for impaired neurosurgical wound healing.
Meningitis: Meningitis occurred in 4% of patients receiving GLIADEL Wafers in the recurrent disease trial. Two cases of meningitis were bacterial; one patient required removal of the Wafers four days after implantation; the other developed meningitis following reoperation for recurrent tumor. One case was diagnosed as chemical meningitis and resolved following steroid treatment. In one case the cause was unspecified, but meningitis resolved following antibiotic treatment. Monitor postoperatively for signs of meningitis and central nervous system infection.
Wafer Migration: GLIADEL Wafer migration can occur. To reduce the risk of obstructive hydrocephalus due to wafer migration into the ventricular system, close any communication larger than the diameter of a Wafer between the surgical resection cavity and the ventricular system prior to Wafer implantation. Monitor patients for signs of obstructive hydrocephalus.
The most common adverse reactions in Newly-Diagnosed High Grade Malignant Glioma patients (incidence >10% and between arm difference ≥4%) are cerebral edema, asthenia, nausea, vomiting, constipation, wound healing abnormalities and depression.
The most common adverse reactions in Recurrent Glioblastoma Multiforme patients (incidence >10% and between arm difference ≥4%) are urinary tract infection, wound healing abnormalities and fever.
Please click here for full Prescribing Information.
Gliadel® is manufactured by Eisai Inc. for Arbor Pharmaceuticals, LLC.
Gliadel® is a registered trademark of Eisai Inc.
June 26 — June 30
Four nights’ accommodation is included in the course fee, and will be booked by the EANS on your behalf. The address of the hotel is:
Lagrange City Apparthotel
81-85, cours Albert Thomas
View: The hotel website
“This hands on course is amazing; very informative and practical; every resident should attend at least one in their training period.” (January 2016)
“Well organised, friendly environment, good run through the basics and more than that. Overall good quality course like you’d expect from an EANS event.”
“Very cost efficient comparing it to other courses that I have attended in the past. The cadaver lab was equipped remarkably well, I never expected to have so many surgical instruments for a cadaver course: tools/ microscopes/ drills! All in abundance! The specimens were the BEST I’ve seen so far! Thanks to the guys in the lab! Gave me the feeling sometimes that It was close to operating on a live human being. Overall, it was by far the best hands on course that I’ve been so far! keep up the good work!”
“The course was fantastic, and was of high standard. If you can maintain this standard with such a relatively low cost, and remarkable cost – benefit ratio, your course will always be one of the best among hands on courses. I fully agree with your policy: preferring cheaper accomodation to more expensive course content.”
“Great organizers and lecturers, amazing lab structure, nice hotel and the best experience exchange with fellow residents you can get. Just do it.” (January 2016)
Terms and Conditions:
Due to high demand for places on the course, payment is required no later than one month before the start of the course. If payment is not received by this time, your place cannot be guaranteed, and may be offered to another candidate.
The registration fee includes all tuition costs, 4 nights’ accommodation in a single room, subsistence throughout the course, a welcome reception and a networking dinner.
If you require an extra night of accommodation – available at an extra charge of €100 – please choose the correct fee type and fill in your arrival and departure details carefully.
Payment can be made either online by credit card, or by bank transfer. Please note that pre-payment is required for this course, no on-site payments will be accepted.
• Cancellations received in writing before 20 days prior to the course start will be reimbursed.
• Cancellations between 20 and 10 days prior to the course – minimum 50% refund.
• Cancellations later than 10 days prior to the course – no refund (unless exceptional extenuating circumstances).